Ho J J, Kim Y S
Gastrointestinal Research Laboratory, Veterans Affairs Medical Center, San Francisco, CA 94121.
Pancreas. 1994 Nov;9(6):674-91. doi: 10.1097/00006676-199411000-00002.
Over 80% of adenocarcinomas of the pancreas originate from duct cells, which are the major source of mucins in the pancreas. Pathological conditions produce changes in the composition and structure of the oligosaccharides of colonic and pancreatic mucins, and it has been suggested that mucins may have a role in the detection of pancreatic cancer. Mucins are now the targets of a number of immunodiagnostic assays for cancer, and their possible use in therapy is being studied. This review describes the structure, biosynthesis, and release of mucins, as well as some of their therapeutic applications. The MUC1 type of mucin is emphasized because it is the main type present in both normal and malignant pancreas and because it is associated with several of the serological pancreatic cancer carbohydrate markers, including CA19-9.
超过80%的胰腺腺癌起源于导管细胞，导管细胞是胰腺中粘蛋白的主要来源。病理状况会导致结肠和胰腺粘蛋白的寡糖组成和结构发生变化，有人提出粘蛋白可能在胰腺癌的检测中发挥作用。粘蛋白现在是多种癌症免疫诊断检测的靶点，并且其在治疗中的潜在用途正在研究中。本综述描述了粘蛋白的结构、生物合成和释放，以及它们的一些治疗应用。重点介绍了MUC1型粘蛋白，因为它是正常胰腺和恶性胰腺中都存在的主要类型，并且它与几种血清学胰腺癌碳水化合物标志物相关，包括CA19-9。
